HBV Core Mutant Screening for cccDNA Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively analyzing the role of the hepatitis B virus core protein in coordinating the alternative fates of mature nucleocapsids and manipulating covalently closed circular DNA (cccDNA) formation for prophylaxis and therapy of HBV infection.
Innovation Solution
A method involving the use of mammalian cell cultures with plasmids encoding mutated HBV core proteins (L60A, I126A, K96A, or combinations thereof) to screen test agents for their ability to reduce cccDNA levels, thereby identifying candidates for reducing HBV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to analyze HBV core protein role and cccDNA formation, then the analysis can be performed, but the methods are inadequate and insufficient for effectively analyzing the role of core protein in coordinating alternative fates of mature nucleocapsids and manipulating cccDNA formation
Solution Approach 1:
The patent segments the analysis system by using separate plasmids to express specific HBV core protein mutants (L60A, I126A, K96A) in distinct cell cultures, allowing independent analysis of each mutant's effect on cccDNA formation. This segmentation enables precise measurement of individual protein function while maintaining overall system manageability.
Solution Approach 2:
The patent changes the parameter of core protein sequence by introducing specific mutations (L60A, I126A, K96A) at defined positions in the HBV core protein. These parameter changes create distinct functional variants that can be systematically analyzed for their effects on nucleocapsid fate and cccDNA formation, improving measurement precision without excessive complexity.
2Productivity
If multiple test agents are screened concurrently using traditional methods, then the screening process can be performed, but the process is time-consuming and inefficient
Solution Approach 1:
The patent merges multiple test agent screenings into a single integrated assay system using the same plasmid-based cell culture platform. By combining testing of multiple agents concurrently in the same experimental framework, the patent improves productivity and reduces total screening time compared to traditional separate testing methods.
Solution Approach 2:
The patent creates a universal screening platform using plasmids that can test multiple different test agents for their ability to reduce cccDNA. This multi-functional system allows simultaneous evaluation of various agents (compounds, antibodies, or other molecules) using the same basic assay protocol, significantly improving screening efficiency.
3Reliability
If traditional screening methods are used to identify agents reducing HBV, then agent identification can be performed, but the methods do not provide sufficient capability for identifying agents that reduce HBV cccDNA production
Solution Approach 1:
The patent replaces complex mechanical or multi-step traditional screening methods with a simplified plasmid-based molecular biology system. By using transfected cell cultures expressing specific HBV core mutants and measuring cccDNA levels through standardized molecular techniques, the patent achieves reliable agent identification with reduced system complexity.
Solution Approach 2:
The patent uses plasmid DNA copies containing specific HBV core protein mutations as standardized test subjects. These plasmid copies provide consistent, reproducible templates for testing agent effects, improving identification accuracy while maintaining relatively simple experimental systems that can be replicated and standardized.
Data Source
AI summary
Provided are compositions and methods for identifying test agents as candidate for use in reducing hepatitis B virus (HBV). The methods involve a) introducing at least one test agent into mammalian cells, the cells having one or more plasmids that encode an HBV genome, wherein the genome includes a segment encoding a mutated HBV core (HBc), wherein the HBc mutation is L60A, I126A, K96A or a combination thereof. The test agent is allowed to be in contact with the mammalian cells for a period of time. Subsequently, amounts of HBV cccDNA in the mammalian cells are determined. The method can be performed in vitro or in vivo. A reduction in cccDNA relative to a control indicates the test agent in the test container is a candidate for reducing HBV in an individual. Cell cultures divided into reaction containers that each contain a distinct test agent are also included.